Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK.
BACKGROUND
We aimed to estimate and externally validate a new UK-specific prognostic model for predicting the long-term risk of a first recurrent event (local recurrence, metastatic recurrence, or second primary breast cancer) in women diagnosed with early breast cancer.


METHODS
Using data on the prognostic characteristics and outcomes of 1844 women treated for early breast cancer at the Churchill Hospital in Oxford, parametric regression-based survival analysis was used to estimate a prognostic model for recurrence-free survival. The model, which incorporated established prognostic factors, was externally validated using independent data. Its performance was compared with that of the Nottingham Prognostic Index (NPI) and Adjuvant! Online.


RESULTS
The number of positive axillary lymph nodes, tumour grade, tumour size and patient age were strong predictors of recurrence. Oestrogen receptor (ER) positivity was shown to afford a moderate protective effect. The model was able to separate patients into distinct prognostic groups, and predicted well at the patient level, mean Brier Accuracy Score=0.17 (s.e.=0.004) and overall C=0.745 (95% CI, 0.717-0.773). Its performance diminished only slightly when applied to a second independent data set. When compared with the NPI, the model was able to better discriminate between women with excellent and good prognoses, and it did not overestimate 10-year recurrence-free survival to the extent observed for Adjuvant! Online.


CONCLUSIONS
The model estimated here predicts well at both the individual patient and group levels, and appears transportable to patients treated at other UK hospitals. Its parametric form permits long-term extrapolation giving it an advantage over other prognostic tools currently in use. A simple point scoring system and reference table allow 5-, 10-, and 15-year predictions from the model to be quickly and easily estimated. The model is also available to download as an interactive computer program.
Campbell
H E
HE
Health Economics Research Centre, Department of Public Health, University of Oxford, Old Road Campus, Headington, Oxford OX3 7LF, UK. helen.campbell@dphpc.ox.ac.uk
Gray
A M
AM
Harris
A L
AL
Briggs
A H
AH
Taylor
M A
MA
D000328:Adult; D000368:Aged; D000465:Algorithms; D001943:Breast Neoplasms / Q000473:pathology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D008962:Models, Theoretical; D011379:Prognosis; D012008:Recurrence; D012306:Risk; D006113:United Kingdom
J Formos Med Assoc. 2000 Sep;99(9):677-83
11000729
Lancet. 1999 Apr 3;353(9159):1132-5
10209976
J Clin Oncol. 2005 Apr 20;23(12):2716-25
15837986
Stat Med. 1999 Mar 30;18(6):681-94
10204197
Br J Cancer. 2003 Aug 18;89(4):605-11
12915864
Br J Cancer. 1987 Oct;56(4):489-92
3689666
Multivariate Behav Res. 1998 Oct 1;33(4):545-71
26753828
Br J Cancer. 2009 Oct 6;101(7):1074-84
19724274
Ann Surg. 2005 Feb;241(2):309-18
15650642
J Clin Oncol. 2002 Dec 15;20(24):4628-35
12488406
Eur J Cancer. 2007 Jul;43(10):1545-7
17320376
Br J Cancer. 1999 Apr;79(11-12):1752-60
10206288
J Clin Epidemiol. 1997 Jan;50(1):21-9
9048687
Qual Life Res. 2001;10(6):479-86
11789549
Lancet. 2005 May 14-20;365(9472):1687-717
15894097
Clin Oncol. 1979 Sep;5(3):227-36
498615
Br J Cancer. 1982 Mar;45(3):361-6
7073932
Psychooncology. 2006 Nov;15(11):1001-13
16511899
J Clin Oncol. 2001 Feb 15;19(4):980-91
11181660
J Natl Cancer Inst. 2007 Apr 4;99(7):516-25
17405996
Stat Med. 1996 Feb 28;15(4):361-87
8668867
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204
16959170
J Clin Epidemiol. 1995 Dec;48(12):1503-10
8543964
Lancet. 2005 Dec 17;366(9503):2087-106
16360786
Breast Cancer Res Treat. 1998;52(1-3):289-303
10066088
Br J Cancer. 2005 Aug 22;93(4):387-91
16106245
Stat Med. 2000 Feb 29;19(4):453-73
10694730
J Clin Oncol. 1994 May;12(5):888-94
8164038
Breast Cancer Res. 2010;12(1):R1
20053270
J Natl Cancer Inst Monogr. 1994;(16):35-42
7999467
Breast Cancer Res Treat. 1992;22(3):207-19
1391987
J Clin Epidemiol. 2003 Jan;56(1):28-37
12589867
Lancet. 1993 Apr 24;341(8852):1039-43
8096955
Lancet. 2002 Apr 13;359(9314):1309-10
11965278
J Natl Cancer Inst. 2007 Apr 4;99(7):506-15
17405995